Literature DB >> 19003918

An abnormal gene expression of the beta-adrenergic system contributes to the pathogenesis of cardiomyopathy in cirrhotic rats.

Giulio Ceolotto1, Italia Papparella, Antonietta Sticca, Sergio Bova, Maurizio Cavalli, Gabriella Cargnelli, Andrea Semplicini, Angelo Gatta, Paolo Angeli.   

Abstract

Decreased cardiac contractility and beta-adrenergic responsiveness have been observed in cirrhotic cardiomyopathy, but their molecular mechanisms remain unclear. To study beta-adrenergic-stimulated contractility and beta-adrenergic gene expression patterns, 20 Wistar Kyoto rats were treated with carbon tetrachloride to induce cirrhosis and 20 rats were used as controls. Left ventricular contractility was recorded in electrically driven isolated hearts perfused at constant flow with isoproterenol (10(-10) to 10(-6) M). A cardiac gene expression profile was obtained using a microarray for the myocyte adrenergic pathway. The cardiac contractility maximal response to isoproterenol was significantly reduced in cirrhotic rats in comparison to control rats, whereas the half-maximal effective concentration was not different. In cirrhotic rats, cardiac gene expression analysis showed a significant overexpression of G protein alpha-inhibiting subunit 2 (Galpha(i2)), cyclic nucleotide phosphodiesterase (PDE2a), regulator of G-protein signaling 2 (RGS2), and down-expression of adenylate cyclase (Adcy3). These results indicate that overexpression of Galpha(i2), PDE2a, and RGS2 down-regulates the beta-adrenergic signaling pathway, thus contributing to the pathogenesis of cirrhotic cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19003918     DOI: 10.1002/hep.22533

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  12 in total

1.  Fas Receptor Activation by Endogenous Opioids Is A New Mechanism for Cardiomyopathy in Cirrhotic Rats.

Authors:  Ata Abbasi; Negar Faramarzi; Mohsen Khosravi; Fatemeh Yazarloo; Mohammad Amin Abbasi; Ahmad R Dehpour; Issa Jahanzad
Journal:  J Clin Exp Hepatol       Date:  2016-10-17

Review 2.  Left ventricular function assessment in cirrhosis: Current methods and future directions.

Authors:  Francisco Sampaio; Joana Pimenta
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

3.  Differential response related to genotoxicity in multiple organs of cirrhotic rats.

Authors:  Marcia R Nagaoka; Luciana Le Sueur-Maluf; Odair Aguiar; Glaucia M Castro; Regina C Spadari-Bratfisch; Daniel A Ribeiro
Journal:  Hepatol Int       Date:  2011-01-06       Impact factor: 6.047

4.  Cardiac structural and functional alterations in infants and children with biliary atresia, listed for liver transplantation.

Authors:  Moreshwar S Desai; Shabier Zainuer; Curtis Kennedy; Debra Kearney; John Goss; Saul J Karpen
Journal:  Gastroenterology       Date:  2011-07-14       Impact factor: 22.682

5.  Hypertrophic cardiomyopathy and dysregulation of cardiac energetics in a mouse model of biliary fibrosis.

Authors:  Moreshwar S Desai; Zainuer Shabier; Michael Taylor; Fong Lam; Sundararajah Thevananther; Astrid Kosters; Saul J Karpen
Journal:  Hepatology       Date:  2010-06       Impact factor: 17.425

6.  Blunted cardiovascular effects of beta-blockers in patients with cirrhosis: Relation to severity?

Authors:  Puria Nabilou; Karen Vagner Danielsen; Nina Kimer; Jens Dahlgaard Hove; Flemming Bendtsen; Søren Møller
Journal:  PLoS One       Date:  2022-06-28       Impact factor: 3.752

7.  Protective role of cardiac-specific overexpression of caveolin-3 in cirrhotic cardiomyopathy.

Authors:  So Yeon Kim; Kang Ho Kim; Jan M Schilling; Joseph Leem; Mehul Dhanani; Brian P Head; David M Roth; Alice E Zemljic-Harpf; Hemal H Patel
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-01-21       Impact factor: 4.052

Review 8.  Cirrhotic cardiomyopathy.

Authors:  Luis Ruiz-del-Árbol; Regina Serradilla
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

Review 9.  Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications.

Authors:  Csaba Matyas; György Haskó; Lucas Liaudet; Eszter Trojnar; Pal Pacher
Journal:  Nat Rev Cardiol       Date:  2020-09-30       Impact factor: 32.419

10.  Herbal Supplement Ameliorates Cardiac Hypertrophy in Rats with CCl(4)-Induced Liver Cirrhosis.

Authors:  Ping-Chun Li; Yung-Wei Chiu; Yueh-Min Lin; Cecilia Hsuan Day; Guang-Yuh Hwang; Peiying Pai; Fuu-Jen Tsai; Chang-Hai Tsai; Yu-Chun Kuo; Hsiao-Chuan Chang; Jer-Yuh Liu; Chih-Yang Huang
Journal:  Evid Based Complement Alternat Med       Date:  2012-11-06       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.